Skip to main content

Open Access Monoclonal Antibody Production in Murine Ascites

I. Clinical and Pathologic Features

Download Article:
(PDF 141.4580078125 kb)
Background and Purpose: Murine ascites production has been associated with appreciable morbidity and mortality, thus raising animal-welfare concerns. To address these concerns, the clinicopathologic changes associated with in vivo production of monoclonal antibodies in mice were characterized, and results were compared among cell lines.

Methods: Five hybridoma cell lines were grown in groups of 20 mice. Fourteen days prior to inoculation with 10 6 hybridoma cells, mice were primed with 0.5 ml of pristane given intraperitoneally; 12 mice were sham treated (controls). Ascites fluid was collected a maximum of three times by abdominal paracentesis. Clinical observations and pre- and postabdominal tap body weights were recorded. Necropsies were performed on all mice.

Results: For all groups combined, overall survival to tap 1 was 98%, to tap 2 was 96%, and to tap 3 was 79%; survival among groups ranged from 90 to 100% for tap 1, 85 to 100% for tap 2, and 35 to 100% for tap 3. Disseminated intra-abdominal seeding with irregular soft tissue and/or solid tumor masses was observed at necropsy.

Conclusions: Significant clinicopathologic changes were associated with monoclonal antibody production in mice, and differences between various hybridoma cell lines were apparent.
No References for this article.
No Supplementary Data.
No Data/Media
No Metrics

Document Type: Research Article

Affiliations: 1: Division of Comparative Medicine, Division of Toxicology, Massachusetts Institute of Technology, Cambridge, Massachusetts 2: Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 3: Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, Memorial Sloan-Kettering Cancer Center and the Cornell University Medical College, 1275 York Avenue, Box 270, New York, NY 10021

Publication date: 1999-02-01

More about this publication?
  • Comparative Medicine (CM), an international journal of comparative and experimental medicine, is the leading English-language publication in the field and is ranked by the Science Citation Index in the upper third of all scientific journals. The mission of CM is to disseminate high-quality, peer-reviewed information that expands biomedical knowledge and promotes human and animal health through the study of laboratory animal disease, animal models of disease, and basic biologic mechanisms related to disease in people and animals.

    Attention Members: To access the full text of the articles, be sure you are logged in to the AALAS website.

    Attention: please note, due to a temporary technical problem, reference linking within the content is not available at this time

  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Membership Information
  • Information for Advertisers
  • For issues prior to 1998
  • Institutional Subscription Activation
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more